Get Started

JAZZ Jazz Pharmaceuticals PLC

105.51

0.00 (0.00%)

Pre Market

Last Updated: 04:05:22

Delayed by 15 minutes

Jazz Pharmaceuticals Gets European Commission OK for Enrylaze

By Ben Glickman

Jazz Pharmaceuticals on Thursday said it had received market authorization from the European Commission for its treatment for certain types of leukemia and lymphoma.

The Dublin-based pharmaceutical company said that Enrylaze could now be used as a component of a multi-agent chemotherapeutic regiment in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.

Enrylaze is currently approved under the name Rylaze in the U.S. and Canada.

The approval from the European Commission was based on Phase 2/3 trial data.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

September 21, 2023 18:05 ET (22:05 GMT)

Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Apr 2024 to May 2024